Guidelines
Neonatal seizures (WHO & ILAE)

Neonatal seizures (WHO & ILAE)

Hot

Updated May 06, 2018

0 0 0 3 0

Comments (0) Resources Add to favorites Follow

Condition(s)

Collection of Evidence

Analysis of Evidence

Graded Recommendations

Strength of Recommendations

Various

see http://www.ilae.org/visitors/centre/documents/Guide-Neonate-WHO.pdf

Neonatal seizures represent one of the most frequent neurological events in newborn infants, often reflecting a variety of different pre, peri-, or postnatal disorders of the central nervous system (CNS). They are also a common manifestation of metabolic abnormality in newborn period and often represent the first sign of neurological dysfunction in neonates. They may be symptomatic or cryptogenic, herald subsequent epilepsy, can be associated with potential morbidity and mortality, and may be used as a factor in considering long-term prognosis. Despite the enormous clinical significance of these events, many aspects of their management are not well supported with evidence-based recommendations.

In particular rather few studies address issues related to the used of antiepileptic drugs (AEDs) such as indications for acute therapy, selection of first-line and second line agents, pharmacokinetics of commonly used AEDs, and duration of treatment after the seizures are controlled on AEDs for neonatal seizures.

The Global Campaign Against Epilepsy, a World Health Organization (WHO) partnership with the International League Against Epilepsy (ILAE) and the International Bureau of Epilepsy (IBE), in collaboration with the Institute for Research on Mental Retardation and Brain Again (IRCCS) named Associazione Oasi Maria SS., a WHO Collaborating Centre for Training and Research in Neuroscience (WHO/CC), initiated a project to develop evidence-based guidelines for the management of neonatal seizures. These guidelines are intended to be of use for neonatologists, paediatric neurologists, paediatricians, general practitioners, nurse practitioners, nurses and other health professionals who may be in contact with infants experiencing seizures within the first 28 days of life (age up to 44 weeks post-conception). The guidelines are framed so as to be applied by health care providers practicing in a wide range of health care facilities, from those with limited resources to tertiary care centres.

The Guideline Developmental Group identified 11 research questions to be of highest priority. Two of these questions were background questions on prevalence of neonatal seizures and predictors of prognosis of neonatal seizures. The remaining 9 questions focused on priority issues related to the management of neonatal seizures. The Grading Recommendations Assessment, Development and Evaluation (GRADE) approach was used for grading the quality of evidence after adaptation to the relevant working area. The quality of the evidence for an outcome was graded as follows: high, moderate, low or very low. After grading the available studies for each outcome, recommendations were formulated on the basis of the summary and quality of evidence, balance between benefits and harms, values and preferences of policy makers, health care providers and parents, feasiblity and resource use; in addition, costs were analysed to see whether they could be qualitatively justifiable by the benefits. The recommendations wre graded into two types: strong and weak. In some cased, the recommendations were context-specific which is indicated in the document as appropriate.

Neonatal seizures (WHO & ILAE)

Attachments

User comments

Join Our Newsletter